PMID- 37408759
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230718
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 14
DP  - 2023
TI  - Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the 
      first-line treatment of advanced non-small cell lung cancer: systematic review 
      and indirect comparison of randomized trials.
PG  - 1172969
LID - 10.3389/fphar.2023.1172969 [doi]
LID - 1172969
AB  - Purpose: Pembrolizumab and tislelizumab have demonstrated significant clinical 
      benefits in first-line treatment for advanced NSCLC. However, no head-to-head 
      clinical trial has ever compared the optimal choice. Therefore, we conducted an 
      indirect comparison to explore the optimal choice for advanced NSCLC combined 
      with chemotherapy. Methods: We conducted a systematic review of randomized 
      trials; the clinical outcomes included overall survival (OS), progression-free 
      survival (PFS), objective response rate (ORR), and adverse events (AEs). Indirect 
      comparisons between tislelizumab and pembrolizumab were conducted with the Bucher 
      method. Results: Data were abstracted from 6 randomized trials involving more 
      than 2,000 participants. Direct meta-analysis showed that both treatment regimens 
      improved clinical outcomes compared with chemotherapy alone (PFS: hazard ratio 
      (HR)(tis+chemo/chemo) 0.55, 95% CI 0.45-0.67; HR(pem+chemo/chemo) 0.53, 95% CI 
      0.47-0.60; ORR: relative risk (RR)(tis+chemo/chemo) 1.50, 95% CI 1.32-1.71; 
      RR(pem+chemo/chemo) 1.89, 95% CI 1.44-2.48). Regarding safety outcomes, 
      tislelizumab and pembrolizumab have a higher risk in the incidence of grade 3 or 
      higher AEs (RR(tis+chemo/chemo) 1.12, 95% CI 1.03-1.21; RR(pem+chemo/chemo) 1.13, 
      95% CI 1.03-1.24). The indirect comparison showed that there was no significant 
      difference between tislelizumab plus chemotherapy and pembrolizumab plus 
      chemotherapy in terms of PFS (HR: 1.04, 95% CI 0.82-1.31), ORR (RR: 0.79, 95% CI 
      0.59-1.07), the incidence of grade 3 or higher AEs (RR 0.99, 95% CI 0.87-1.12), 
      and AEs leading to death (RR 0.70, 95% CI 0.23-2.09). In progression-free 
      survival subgroup analysis, the results demonstrate no significant differences in 
      PFS by PD-L1 TPS expression level, age, liver metastasis status, and smoking 
      status between tislelizumab plus chemotherapy and pembrolizumab plus 
      chemotherapy. Conclusion: The efficacy and safety of tislelizumab combination 
      chemotherapy were not substantially different from pembrolizumab combination 
      chemotherapy.
CI  - Copyright (c) 2023 Guo, Jia, Hao and Yang.
FAU - Guo, Yimeng
AU  - Guo Y
AD  - Department of Pharmacy, Shanxi Province Cancer Hospital/ Shanxi Hospital 
      Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer 
      Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi Province, 
      China.
FAU - Jia, Junting
AU  - Jia J
AD  - Department of Pharmacy, Shanxi Province Cancer Hospital/ Shanxi Hospital 
      Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer 
      Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi Province, 
      China.
FAU - Hao, Zhiying
AU  - Hao Z
AD  - Department of Pharmacy, Shanxi Province Cancer Hospital/ Shanxi Hospital 
      Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer 
      Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi Province, 
      China.
FAU - Yang, Jing
AU  - Yang J
AD  - Department of Pharmacy, Shanxi Province Cancer Hospital/ Shanxi Hospital 
      Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer 
      Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi Province, 
      China.
LA  - eng
PT  - Systematic Review
DEP - 20230620
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC10318343
OTO - NOTNLM
OT  - immunotherapy
OT  - non-small cell lung cancer
OT  - pembrolizumab
OT  - programmed cell death 1 receptor
OT  - tislelizumab
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/07/06 06:42
MHDA- 2023/07/06 06:43
PMCR- 2023/06/20
CRDT- 2023/07/06 04:05
PHST- 2023/02/24 00:00 [received]
PHST- 2023/06/12 00:00 [accepted]
PHST- 2023/07/06 06:43 [medline]
PHST- 2023/07/06 06:42 [pubmed]
PHST- 2023/07/06 04:05 [entrez]
PHST- 2023/06/20 00:00 [pmc-release]
AID - 1172969 [pii]
AID - 10.3389/fphar.2023.1172969 [doi]
PST - epublish
SO  - Front Pharmacol. 2023 Jun 20;14:1172969. doi: 10.3389/fphar.2023.1172969. 
      eCollection 2023.